markets
  • International Prospect Ventures Ltd. (IZZ) has completed a non-brokered private placement offering for gross proceeds of $500,000
  • The company issued 10 million units for $0.05 per unit
  • The company paid cash finder’s fees of $1,250 and issued 25,000 finder’s warrants
  • Proceeds will be used for general corporate purposes and to advance gold tenements in Western Australia
  • International Prospect Ventures Ltd. (IZZ) is unchanged, trading at $0.04 per share as of 2:03 p.m. EST

International Prospect Ventures (IZZ) has completed a previously-announced non-brokered private placement offering for gross proceeds of $500,000.

The company issued 10 million units at $0.05 per unit. Each unit consists of one common share and half of one non-transferable share purchase warrant. A whole warrant entitles the holder to purchase one additional common share for $0.075 per share for the first year, then $0.10 per share from December 9th, 2023, until December 8th, 2024.

Six company insiders participated in the offering for an aggregate cash consideration of $222,000.

The company paid finder’s fees in the amount of $1,250 and issued 25,000 finder’s warrants exercisable for one year.

The net proceeds raised will be used for general corporate purposes and to advance the company’s gold tenements in Western Australia.

International Prospect is a natural resource issuer involved in the process of acquiring and exploring mineral property assets. It owns several properties in Canada, for which it is seeking partners to form joint ventures with or for outright sales transactions.

International Prospect Ventures Ltd. (IZZ) is unchanged, trading at $0.04 per share as of 2:03 p.m. EST.


More From The Market Online

Three stocks with multi-bagger potential

The best investors stick to stocks with the most easily discernible reasons in support of their multi-bagger potential.

Junior gold CEO signals conviction with new investment

Cynthia Le Sueur-Aquin, CEO of junior gold stock Laurion Mineral Exploration (TSXV:LME), will exercise 750,000 stock options for C$142,500.

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.